Frontline Treatment for Newly Diagnosed Lower-Risk Myelodysplastic Syndromes (LR-MDS)
home / precision-medicine / frontline-treatment-for-newly-diagnosed-lower-risk-myelodysplastic-syndromes-lr-mds
Panelists discuss how emerging therapies, including luspatercept, are reshaping the front-linefrontline treatment landscape for lower-risk myelodysplastic syndromes (LR-MDS), with a focus on personalized approaches, prognostic scoring, and the improvement of anemia management and patient quality of life.
EP. 2: Defining LR-MDS: Initial Patient Presentation and Updates in MDS Risk.
December 11th 2024Panelists discuss how the initial presentation of lower-risk myelodysplastic syndromes (LR-MDS) involves anemia and other cytopenias, with updates on MDS risk assessment using prognostic scoring systems like such as IPSS-R and IPSS-M to guide treatment decisions.
Watch
